FCDI manufactures human induced pluripotent stem cells (iPSCs), which are skin or blood cells that scientists reprogram back into their embryonic state and then coax into specific cell types for use in scientific research or drug development. FCDI has called Madison home since it’s founding in 2004, and specifically has called the University Research Park its home. So when they needed increased space to house their new stem cell production, they oped to remodel a neighboring building in the park.
This new facility will allow for the manufacturing of stem cell therapies that can be used as regenerative medicine — cells that can repair or rebuild a patient’s diseased or damaged tissue. It is a combination of office and lab spaces including ISO 7 level cleanrooms. The project was completed on an accelerated, phased construction schedule of an occupied building and included the coordination of specialized owner-direct purchase equipment.
This new facility will speed the development of stem cell therapies in its pipeline as well as provide job opportunities for highly skilled personnel in Madison. FCDI will continue to leverage its technologies and knowledge of iPS cells — working together with academic institutions and corporations around the world to advance the field of regenerative medicine with the hope of providing new therapies for patients.
*Due to the sensitive and confidential nature of this project, photo shown here is a purchased stock photo and is not intended to be representative of Fujifilm Cellular Dynamics, Inc.